Gerber, David E <br/><br/>
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  01 2020 
 - 60-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2019.10.033  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma of Lung--drug therapy<br/>Benzamides--therapeutic use<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Focal Adhesion Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Follow-Up Studies<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Prognosis<br/>Prospective Studies<br/>Proto-Oncogene Proteins p21(ras)--genetics<br/>Pyrazines--therapeutic use<br/>Salvage Therapy<br/>Sulfonamides--therapeutic use<br/>Survival Rate